Enhancing antidepressant safety surveillance: comparative analysis of adverse drug reaction signals in spontaneous reporting and healthcare claims databases

被引:1
|
作者
Kim, Taehyung [1 ,2 ]
Jiang, Xinying [3 ,4 ]
Noh, Youran [1 ,2 ]
Kim, Maryanne [1 ,2 ]
Hong, Song Hee [1 ,2 ]
机构
[1] Seoul Natl Univ, Colleage Pharm, Seoul, South Korea
[2] Seoul Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, Seoul, South Korea
[3] Healthcare & Life Sci China, Shanghai, Peoples R China
[4] Renaissance Grp, Shanghai, Peoples R China
基金
新加坡国家研究基金会;
关键词
signal detection; drug safety surveillance; spontaneous reporting system; healthcare claim database; antidepressant; adverse drug reaction; pharmacovigilance; LARGE FREQUENCY TABLES; PERFORMANCE; SYSTEMS;
D O I
10.3389/fphar.2023.1291934
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background/Objective: Spontaneous reporting systems (SRS) such as the Korea Adverse Event Reporting System (KAERS) are limited in their ability to detect adverse drug reaction (ADR) signals due to their limited data on drug use. Conversely, the national health insurance claim (NHIC) data include drug use information for all qualifying residents. This study aimed to compare ADR signal profiles for antidepressants between KAERS and NHIC, evaluating the extent to which detected signals belong to common ADRs and labeling information.Materials and Methods: ADR signal detection in KAERS and NHIC databases, spanning January to December 2017, employed disproportionality analysis. Signal classes were determined based on System Organ Class (SOC) of the Medical Dictionary for Regulatory Activities (MedDRA). Also, Common ADR Coverage (CAC), the proportion of detected signals deemed common ADRs, and labeling information coverage (LIC) represented by mean average precision (mAP) were calculated. Additionally, protopathic bias and relative risk (RR) evaluation were performed to check for signal robustness.Results: Signal detection revealed 51 and 62 signals in KAERS and NHIC databases, respectively. Both systems predominantly captured signals related to nervous system disorders, comprising 33.3% (N = 17) in KAERS and 50.8% (N = 31) in NHIC. Regarding the type of antidepressants, KAERS predominantly reported signals associated with tricyclic antidepressants (TCAs) (N = 21, 41.2%), while NHIC produced most signals linked to selective serotonin reuptake inhibitors (SSRIs) (N = 22, 35.5%). KAERS exhibited higher CAC (68.63% vs. 29.03%) than NHIC. LIC was also higher in KAERS than in NHIC (mAP for EB05: 1.00 vs. 0.983); i.e., NHIC identified 5 signals not documented in drug labeling information, while KAERS found none. Among the unlabeled signals, one (Duloxetine-Myelopathy) was from protopathic bias, and two (duloxetine-myelopathy and tianeptine-osteomalacia) were statistically significant in RR.Conclusion: NHIC exhibited greater capability in detecting ADR signals associated with antidepressant use, encompassing unlabeled ADR signals, compared to KAERS. NHIC also demonstrated greater potential for identifying less common ADRs. Further investigation is needed for signals detected exclusively in NHIC but not covered by labeling information. This study underscores the value of integrating different sources of data, offering substantial regulatory insights and enriching the scope of pharmacovigilance.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia
    Wahab, Izyan A.
    Pratt, Nicole L.
    Kalisch, Lisa M.
    Roughead, Elizabeth E.
    DRUG SAFETY, 2014, 37 (01) : 53 - 64
  • [22] Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia
    Izyan A.Wahab
    Nicole L. Pratt
    Lisa M. Kalisch
    Elizabeth E. Roughead
    Drug Safety, 2014, 37 : 53 - 64
  • [23] Patterns of adverse drug reaction reporting in Ethiopia: A database analysis of spontaneous reports from 2013 to 2018
    Anebo, Zelalem Gebretsadik
    Abacioglu, Nurrettin
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2022, 15 (02) : 56 - 62
  • [24] An Intervention to Improve Spontaneous Adverse Drug Reaction Reporting by Hospital PhysiciansA Time Series Analysis in Spain
    Consuelo Pedrós
    Antoni Vallano
    Gloria Cereza
    Gemma Mendoza-Aran
    Antònia Agustí
    Cristina Aguilera
    Immaculada Danés
    Xavier Vidal
    Josep M. Arnau
    Drug Safety, 2009, 32 : 77 - 83
  • [25] An Intervention to Improve Spontaneous Adverse Drug Reaction Reporting by Hospital Physicians A Time Series Analysis in Spain
    Pedros, Consuelo
    Vallano, Antoni
    Cereza, Gloria
    Mendoza-Aran, Gemma
    Agusti, Antonia
    Aguilera, Cristina
    Danes, Immaculada
    Vidal, Xavier
    Arnau, Josep M.
    DRUG SAFETY, 2009, 32 (01) : 77 - 83
  • [26] Patterns of adverse drug reaction reporting in Ethiopia: A database analysis of spontaneous reports from 2013 to 2018
    Zelalem Gebretsadik Anebo
    Nurrettin Abacioglu
    Asian Pacific Journal of Tropical Medicine, 2022, (02) : 56 - 62
  • [27] Identification of novel safety signals of SGLT2 inhibitors: A pharmacovigilance analysis of the USFDA and global adverse event reporting databases
    Hibathulla, P.
    Undela, Krishna
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 241 - 242
  • [28] Does Pharmacy Students' Education in Postmarketing Adverse Drug Reaction Reporting Influence Post-Graduate Drug Safety Surveillance Training Plans?
    Kim, Jean
    Perna, Nicole L.
    Viteri, Yvonne
    Oladipo, Anthony G.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S82 - S82
  • [29] Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System
    Crisafulli, Salvatore
    Cutroneo, Paola Maria
    Luxi, Nicoletta
    Fontana, Andrea
    Ferrajolo, Carmen
    Marchione, Pasquale
    Sottosanti, Laura
    Zanoni, Giovanna
    Moretti, Ugo
    Franze, Silvia
    Minghetti, Paola
    Trifiro, Gianluca
    DRUG SAFETY, 2023, 46 (04) : 343 - 355
  • [30] Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System
    Salvatore Crisafulli
    Paola Maria Cutroneo
    Nicoletta Luxi
    Andrea Fontana
    Carmen Ferrajolo
    Pasquale Marchione
    Laura Sottosanti
    Giovanna Zanoni
    Ugo Moretti
    Silvia Franzè
    Paola Minghetti
    Gianluca Trifirò
    Drug Safety, 2023, 46 : 343 - 355